Acumen Pharmaceuticals, Inc. (ABOS) Stock Forecast & Price Target

Acumen Pharmaceuticals, Inc. (ABOS) has an ST Score of 34.9 (C-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate ABOS a Buy, with a price target of $7.00 (+213.2% vs the current price). Our ST Score grades it C- (34.9/100). The ST Score is a data-driven signal, not a recommendation.

Valuation B-, Profitability F, Financial Strength D-, Momentum C+, Growth D+, Forecast A.

Acumen Pharmaceuticals, Inc. (ABOS) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Acumen Pharmaceuticals, Inc. (ABOS) earns a growth grade of D+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Acumen Pharmaceuticals, Inc. (ABOS) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Acumen Pharmaceuticals, Inc. (ABOS) earns a financial strength grade of D-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Acumen Pharmaceuticals, Inc. (ABOS) is $7.00 from 8 analysts, which is +213.2% versus the recent price of $2.23.

Acumen Pharmaceuticals, Inc. (ABOS) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.